we detected epithelial-mesenchymal transition (EMT) markers and found that mesenchymal marker proteins (vimentin and β-catenin) and associated EMT transcription factors (Snail and Slug) were downregulated in A2780cis cells after treated by Bevacizumab or/and Atezolizumab, while the epithelial marker E-cadherin was up-regulated, especially under the combination of them (Figure 4G), which indicated Bevacizumab and Atezolizumab inhibit EMT in cisplatin resistant ovarian cancer cells. This evidence concerns the gene VIM and ovarian cancer.